Zebrafish Model of Steatosis (NAFLD) and Steatohepatitis (NASH)
Non-Alcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH) has been established now in Zebrafish. NASH characterized by Lobular Inflammation; Hepatocyte Ballooning and Degeneration progressing to Liver Fibrosis is fully reproducible in Zebrafish. Zebrafish models of NASH - diet inducted and choline deficient are proving to be translatable NASH Animal Models. A single Zebrafish model of Non-Alcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH) can be employed to screen Anti-Fibrotic Compounds in Animal Models of NASH which can also progress to Cirrhosis and Hepatocellular Carcinoma. The translation efficiency of Non-Alcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH) in zebrafish is established by replication of pathogenesis proceeds as in humans. Non-Alcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH) in zebrafish is characterized by Accumulation of Fat, visceral Adiposity, Insulin Resistance, Dyslipidemia and associated with Obesity, Insulin Resistance, Glucose Intolerance, Type 2 Diabetes, High Cholesterol and High triglycerides as a Metabolic Syndrome. Non-Alcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH) in zebrafish Model can be used to measure risk factor as well, since pathogenesis and Molecular Basis are well established hence increasing the overall impact on NASH and NAFLD drug development. View our posters on Zebrafish model of (NAFLD) and Steatohepatitis (NASH) below.
Established Scientific Hypothesis of NASH : The progress of the disease is in the order of obesity followed by insulin resistance, steatosis, inflammation, apoptosis and fibrosis.
Pentagrit Model Description: Wildtype juvenile fish are fed with high cholesterol diet from the period of 6 weeks.6 weeks after induction, NASH phenotype is observed. The fish is graded and experimental groups can be set. Key phenotype observations includes increased liver size as % of body weight, deviation in ALT, hepatomegaly with proceeds to steatosis and ballooning.
Oral Dosing Outcomes: 25mg (Translated Dose) of OCA given for 3 weeks in Zebrafish is equivalent to a 72 week study period in humans. The outcomes were statistical significant improvements in histological endpoints leading to decrease in the NAFLD Activity Score, with no worsening of fibrosis. Also administration of OCA at 25 mg (Translated Dose) daily for 1 week reduced markers of liver inflammation and also increased insulin sensitivity similar to that of the study in humans.
Managing Adverse Effects: Maximum tolerable dose for high cholesterol groups and QT interval studies can be performed to evaluate long-term safety issues for the concomitant use of statins in OCA treatment.
NASH Liver Biopsy: Red O stained liver sections of DIO NASH Zebrafish showing lipid accumulation correlations with an increase in gross liver size. The progress is with an increased Liver/Body weight ratio reaching to a window of ratio 0.022 between WT and NASH Zebrafish. NASH progress is also with an increasingly yellow colored liver indicating fat accumulation. Quantitative determinations using chemometric method identified a severe steatosis with >67% fat in NASH zebrafish.
Zebrafish NASH Model - Progression of Pathology
Zebrafish Model of NASH is induced through a precise knockout of genes that predispose the animal to NASH. Following a knock out of the selected gene, the animal may be fed with enriched diet to drive the require NASH pathophysiology. Zebrafish NASH Model can therefore carry the metabolic environment and the genetic predisposition exactly as the disease progress in humans. Zebrafish NASH Model as an alternative model of NASH is an accelerator for NASH Models in smaller animals or High Fat Diet NASH Model Models. The industry standard NASH model is homogenous and may not represent the entire population. The heterogenous NASH model in zebrafish therefore covers a wide range of pathophysiology as observed in the population. In this case it also models DIO Zebrafish (diet induced obese zebrafish), STAM animal model, rodent models of fatty liver diseases and other NASH Models.
NASH Model Trials in Zebrafish
Zebrafish NASH Model as an alternative model of NASH could be further refined as per genetic predisposition. An animal trial study would consist of multiple arms with subjects carrying atleast one gene that predispose a NASH mileu. Therefore a single study group of animals is able to represent the the heterogeneity of human population.Below are genes that could be selectively knocked out in Zebrafish Model of NASH.